Clinical Trial Update: Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

This update reports the completion and posted results of a Phase 1/2 trial evaluating the safety and efficacy of the CAR-T therapy JCARH125 in patients with rel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• JCARH125

Snippet

Sponsor: Juno Therapeutics, a Subsidiary of Celgene | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-05-24